3 Australian Mining Stocks Trading Below Fair Value Right Now

UK GDP just surprised to the upside in Q2, which shows that some advanced economies still have pockets of resilience even as inflation stays in focus. That mix can keep investors hunting for growth at sensible price points. Financially Fit Penny Stocks aims to surface lower priced companies with healthier balance sheets. This article highlights 3 stocks from the screener that may be worth a closer look now.

The three stocks in this article are just a starting sample, and the full Financially Fit Penny Stocks screen highlights around 400 more companies with equally compelling stories that are not covered here. To go straight to the source, analyze and identify your own high conviction ideas through the Financially Fit Penny Stocks screener.

Ora Banda Mining is a Subiaco based miner focused on exploring and operating gold and base metal projects in Western Australia, anchored by its 100% owned Davyhurst Gold Project near Kalgoorlie. The company generates all of its A$554 million in revenue from gold production and exploration, entirely within Australia. At a market cap of about A$2.6b, Ora Banda Mining now sits firmly in mid cap territory on the ASX.

Investors looking at Ora Banda Mining can see a business that combines recent earnings momentum with a relatively low P/E multiple compared with both peers and the broader metals and mining sector. This sits alongside a Simply Wall Street fair value estimate that is above the current share price. That is supported by high net margins, returns on equity and an expanding resource base at Davyhurst, including new reserves at Round Dam and Waihi and intensive drilling plans through 2027. The trade off is a higher risk profile, with sizable non cash earnings and reliance on external borrowing. This makes it important to understand how sustainable this phase is before forming a firm view on the stock.

Ora Banda Mining’s earnings momentum and low P/E can look like a clear mispricing, yet the heavy non cash earnings and debt reliance raise sharper questions. See how the 4 key rewards and 1 important major warning sign could change the whole story

Build your own low P/E and quality shortlist

Ora Banda Mining and the other two stocks in this article all came out of a single Simply Wall St screen, but the real value is in setting filters that fit your own approach. Use our flexible Screener to combine valuation, quality, balance sheet and risk metrics, or start with any of our curated Investing Ideas for ready made shortlists that are already mapped out.

Alkane Resources is a long-established Australian gold producer that now also has exposure to copper, nickel, zinc and silver, along with investments in smaller gold projects. The company has grown into a multi mine platform backed by a market cap of about A$2.2b, which puts it in the mid cap bracket on the ASX.

Alkane Resources may appeal to investors who want a mix of current cash generation and long term project exposure in one stock. Analyst estimates cited in the market suggest earnings and revenue are both forecast to grow faster than the wider Australian market, while the shares trade at a discount to one independent cash flow estimate and carry a P/E close to the sector average. The trade-off is higher balance sheet risk from external borrowing and a more complex three mine structure, with the Boda Kaiser build planned as a major next step. For investors weighing that combination of growth potential, valuation gap and funding risk, there is significantly more detail to consider in Alkane’s full investment case.

Alkane Resources sits at the crossroads of cash generation today and multi mine expansion tomorrow, yet the real story sits in the detailed funding and project assumptions inside the analysis report for Alkane Resources.

Sigma Healthcare runs one of Australia’s largest pharmacy networks as a franchisor and wholesaler, supplying community pharmacies and online channels under brands such as Chemist Warehouse, Amcal and Discount Drug Stores. The company generates about A$9.5b a year from healthcare activities, and is currently valued by the market at around A$34.3b. For investors, it is essentially a large scale medicines, health products and services distributor wrapped around well known retail pharmacy brands.

Sigma Healthcare combines solid earnings growth over the past five years with forecasts for double digit earnings and high single digit revenue growth. At the same time, profit margins have tightened, returns on equity sit in the low range and the P/E multiple is high compared with peers, which suggests expectations are already reflected in the share price. The company relies entirely on external borrowings and has a relatively fresh and less independent board, which can raise governance and funding questions. Sigma’s decision to step back from the proposed Boots acquisition also leaves open what its next major overseas move could be. That unanswered question is exactly where more detailed research can pay off for you as an investor.

Sigma Healthcare’s earnings profile and rich P/E suggest investors may be missing a key piece of the growth story. For the full context on margins, funding and governance, see the analysis report for Sigma Healthcare.

Seeking Fresh Alternatives Beyond These Picks

Some of the most interesting stocks start moving before they hit the headlines. Consider these ideas while they are still under the radar and review them promptly.

• Target companies with strong cash generation and pricing power by scanning our curated 4 dividend fortresses that aim to keep income flowing even when sentiment shifts.
• Review long term demand for critical materials and production capacity with a focused pass through the 9 top copper producer stocks that zeroes in on financially healthier operators.
• Evaluate potential infrastructure momentum by checking the hand picked 35 power grid technology and infrastructure stocks that concentrates on balance sheet strength and funding flexibility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com